ASMB — Assembly Biosciences, Inc. stock price, charts and financials

QT51Assembly Biosciences, Inc.

Assembly Biosciences, Inc. (NASDAQ: ASMB) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
26.61
-0.07-0.26%
OverviewShort InterestFilings
ASMBQT51Assembly Biosciences, Inc.·NASDAQ
26.61-0.26%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.33%$15.48MESO+4.96%$16.73ZBIO-1.46%$31.96GHRS-2.07%$29.64TSHA-0.69%$6.51STOK-1.46%$32.23ABCL+31.03%$9.08VRDN-2.29%$23.05
Snapshot
Index-P/E-EPS (ttm)-0.58Insider Own-Shs Outstand15.89MPerf Week6.25%
Market Cap424.02MForward P/E-EPS next Y-3.21Insider Trans-0.00%Shs Float8.59MPerf Month-4.27%
Enterprise Value395.39MPEG-EPS next Q-Inst Own-Short Float26.90%Perf Quarter-13.74%
Income-6.02MP/S5.96EPS this Y-193.39%Inst Trans-Short Ratio11.59Perf Half Y5.08%
Sales71.10MP/B2.27EPS next Y-88.60%ROA-2.71%Short Interest2.31MPerf YTD-21.55%
Book/sh-P/C-EPS next 5Y-ROE-4.21%52W High39.60 -32.81%Perf Year37.31%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-6.74%52W Low19.08 39.47%Perf 3Y100.30%
Dividend Est.-EV/EBITDA-Sales past 3/5Y- -1.84%Gross Margin53.91%Volatility3.46% 4.65%Perf 5Y-35.93%
Dividend TTM-EV/Sales5.56EPS Y/Y TTM91.33%Oper. Margin-19.05%ATR (14)1.26Perf 10Y-62.63%
Dividend Ex-Date-Quick Ratio6.65Sales Y/Y TTM144.83%Profit Margin-8.98%RSI (14)53.36Recom2.45
Dividend Gr. 3/5Y-Current Ratio6.65EPS Q/Q53.85%SMA202.48%Beta1.07Target Price45.00
Payout0.00%Debt/Eq0.01Sales Q/Q-11.11%SMA503.68%Rel Volume0.60Prev Close26.68
Employees73LT Debt/Eq0.01EarningsAug 05SMA200-8.53%Avg Volume198.61KPrice26.61
IPO DateDec 17, 2010Option/ShortYes / YesEPS/Sales Surpr.16.92% -11.36%Net Debt/EBITDA4.57Volume119,771Change-0.26%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-15-26ReiteratedMizuhoOutperform$40 → $45
Nov-20-25ReiteratedMizuhoOutperform$36 → $40
Sep-24-25InitiatedCitizens JMPOutperform$38
Sep-24-24ReiteratedMizuho SecuritiesBuy$36
Sep-20-24ReiteratedJefferiesHold$35
Oct-23-22DowngradeTruist SecuritiesBuy → Hold
Sep-01-21DowngradeWilliam BlairOutperform → Market Perform
Mar-22-21DowngradeSVB LeerinkOutperform → Market Perform
Nov-05-20DowngradeJefferiesBuy → Hold
Oct-08-18UpgradeB. Riley FBRNeutral → Buy
Latest News
Company

Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue717229——————
Cost of Goods Sold Incl. D&A33056——————
Gross Profit3872-27——————
Selling, General and Administrative Excl. Other202018——————
Research and Development656556——————
Other Operating Expense-32-1-56——————
Operating Income-13-12-45——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)766——————
Net Income Before Taxes-6-6-40——————
Income Taxes
000——————
Consolidated Net Income-6-6-40——————
Net Income From Continuing Operations-6-6-40——————
Net Income-6-6-40——————
EPS (Recurring)-0.58-0.55-6.69——————
EPS (Basic, Before Extraordinaries)-0.58-0.55-6.69——————
EPS (Diluted)-0.58-0.55-6.69——————
EBITDA-6-6-40——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio6.375.203.26——————
Gross Margin53.52100.00-93.10——————
Operating Margin-18.31-16.67-155.17——————
Net Margin-8.45-8.33-137.93——————
Shares Outstanding17116——————
Market Capitalization45237495——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$42.15$34.24$26.33$18.41$10.50● Close Price0.00M12.40M24.80M37.20M49.59MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Bjorkquist Jeanette MPFO and PAOJun 17 '26Sale23.252967414,560Jun 18
White Nicole SChief Manufacturing OfficerMar 30 '26Sale26.691975,25737,477Mar 31
Bjorkquist Jeanette MPFO and PAOMar 30 '26Sale26.693288,75511,089Mar 31
GILEAD SCIENCES, INC.10% OwnerAug 08 '25Buy10.804,591,84049,594,1684,505,391Oct 03
McHutchison John GDirectorMar 31 '25Sale9.857577,45518,347Apr 15
Okazaki Jason ACEO and PresidentMar 31 '25Sale9.853553,49614,757Apr 01
Bjorkquist Jeanette MPrincipal Accounting OfficerMar 31 '25Sale9.851801,7734,617Apr 01
White Nicole SChief Manufacturing OfficerMar 31 '25Sale9.851971,94011,674Apr 01
Houghton MichaelDirectorDec 30 '24Buy15.613,20249,9983,202Dec 31
GILEAD SCIENCES, INC.10% OwnerDec 19 '24Buy21.37940,49920,098,4642,209,471Dec 23
Schornstein Alexander10% OwnerNov 25 '24Buy14.917,976118,890728,113Nov 26
Schornstein Alexander10% OwnerNov 22 '24Buy14.8717,024253,104720,137Nov 26
White Nicole SChief Manufacturing OfficerNov 18 '24Sale16.294065211,871Nov 19
Schornstein Alexander10% OwnerOct 08 '24Buy14.5810,000145,800703,113Oct 09
Okazaki Jason ACEO and PresidentOct 03 '24Sale14.811972,91814,904Oct 04
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.